Cargando…

Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa

Background: Following the World Health Organization (WHO) recommendation, 38/47 countries have introduced rotavirus vaccines into the program of immunization in the WHO Regional Office for Africa (WHO/AFRO). Initially, two vaccines (Rotarix and Rotateq) were recommended and recently two additional v...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandomando, Inacio, Augusto Messa, Biey, Joseph Nsiari-Muzeyi, Paluku, Gilson, Mumba, Mutale, Mwenda, Jason M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140870/
https://www.ncbi.nlm.nih.gov/pubmed/37112700
http://dx.doi.org/10.3390/vaccines11040788
_version_ 1785033256659320832
author Mandomando, Inacio
Augusto Messa,
Biey, Joseph Nsiari-Muzeyi
Paluku, Gilson
Mumba, Mutale
Mwenda, Jason M.
author_facet Mandomando, Inacio
Augusto Messa,
Biey, Joseph Nsiari-Muzeyi
Paluku, Gilson
Mumba, Mutale
Mwenda, Jason M.
author_sort Mandomando, Inacio
collection PubMed
description Background: Following the World Health Organization (WHO) recommendation, 38/47 countries have introduced rotavirus vaccines into the program of immunization in the WHO Regional Office for Africa (WHO/AFRO). Initially, two vaccines (Rotarix and Rotateq) were recommended and recently two additional vaccines (Rotavac and Rotasiil) have become available. However, the global supply challenges have increasingly forced some countries in Africa to switch vaccine products. Therefore, the recent WHO pre-qualified vaccines (Rotavac, Rotasiil) manufactured in India, offer alternatives and reduce global supply challenges related to rotavirus vaccines; Methods: Using a questionnaire, we administered to the Program Managers, Expanded Program for Immunization, we collected data on vaccine introduction and vaccine switch and the key drivers of the decisions for switching vaccines products, in the WHO/AFRO. Data was also collected fromliterature review and the global new vaccine introduction status data base maintained by WHO and other agencies. Results: Of the 38 countries that introduced the vaccine, 35 (92%) initially adopted Rotateq or Rotarix; and 23% (8/35) switched between products after rotavirus vaccine introduction to either Rotavac (n = 3), Rotasiil (n = 2) or Rotarix (n = 3). Three countries (Benin, Democratic Republic of Congo and Nigeria) introduced the rotavirus vaccines manufactured in India. The decision to either introduce or switch to the Indian vaccines was predominately driven by global supply challenges or supply shortage. The withdrawal of Rotateq from the African market, or cost-saving for countries that graduated or in transition from Gavi support was another reason to switch the vaccine; Conclusions: The recently WHO pre-qualified vaccines have offered the countries, opportunities to adopt these cost-effective products, particularly for countries that have graduated or transitioning from full Gavi support, to sustain the demand of vaccines products.
format Online
Article
Text
id pubmed-10140870
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101408702023-04-29 Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa Mandomando, Inacio Augusto Messa, Biey, Joseph Nsiari-Muzeyi Paluku, Gilson Mumba, Mutale Mwenda, Jason M. Vaccines (Basel) Brief Report Background: Following the World Health Organization (WHO) recommendation, 38/47 countries have introduced rotavirus vaccines into the program of immunization in the WHO Regional Office for Africa (WHO/AFRO). Initially, two vaccines (Rotarix and Rotateq) were recommended and recently two additional vaccines (Rotavac and Rotasiil) have become available. However, the global supply challenges have increasingly forced some countries in Africa to switch vaccine products. Therefore, the recent WHO pre-qualified vaccines (Rotavac, Rotasiil) manufactured in India, offer alternatives and reduce global supply challenges related to rotavirus vaccines; Methods: Using a questionnaire, we administered to the Program Managers, Expanded Program for Immunization, we collected data on vaccine introduction and vaccine switch and the key drivers of the decisions for switching vaccines products, in the WHO/AFRO. Data was also collected fromliterature review and the global new vaccine introduction status data base maintained by WHO and other agencies. Results: Of the 38 countries that introduced the vaccine, 35 (92%) initially adopted Rotateq or Rotarix; and 23% (8/35) switched between products after rotavirus vaccine introduction to either Rotavac (n = 3), Rotasiil (n = 2) or Rotarix (n = 3). Three countries (Benin, Democratic Republic of Congo and Nigeria) introduced the rotavirus vaccines manufactured in India. The decision to either introduce or switch to the Indian vaccines was predominately driven by global supply challenges or supply shortage. The withdrawal of Rotateq from the African market, or cost-saving for countries that graduated or in transition from Gavi support was another reason to switch the vaccine; Conclusions: The recently WHO pre-qualified vaccines have offered the countries, opportunities to adopt these cost-effective products, particularly for countries that have graduated or transitioning from full Gavi support, to sustain the demand of vaccines products. MDPI 2023-04-03 /pmc/articles/PMC10140870/ /pubmed/37112700 http://dx.doi.org/10.3390/vaccines11040788 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Mandomando, Inacio
Augusto Messa,
Biey, Joseph Nsiari-Muzeyi
Paluku, Gilson
Mumba, Mutale
Mwenda, Jason M.
Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa
title Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa
title_full Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa
title_fullStr Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa
title_full_unstemmed Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa
title_short Lessons Learned and Future Perspectives for Rotavirus Vaccines Switch in the World Health Organization, Regional Office for Africa
title_sort lessons learned and future perspectives for rotavirus vaccines switch in the world health organization, regional office for africa
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140870/
https://www.ncbi.nlm.nih.gov/pubmed/37112700
http://dx.doi.org/10.3390/vaccines11040788
work_keys_str_mv AT mandomandoinacio lessonslearnedandfutureperspectivesforrotavirusvaccinesswitchintheworldhealthorganizationregionalofficeforafrica
AT augustomessa lessonslearnedandfutureperspectivesforrotavirusvaccinesswitchintheworldhealthorganizationregionalofficeforafrica
AT bieyjosephnsiarimuzeyi lessonslearnedandfutureperspectivesforrotavirusvaccinesswitchintheworldhealthorganizationregionalofficeforafrica
AT palukugilson lessonslearnedandfutureperspectivesforrotavirusvaccinesswitchintheworldhealthorganizationregionalofficeforafrica
AT mumbamutale lessonslearnedandfutureperspectivesforrotavirusvaccinesswitchintheworldhealthorganizationregionalofficeforafrica
AT mwendajasonm lessonslearnedandfutureperspectivesforrotavirusvaccinesswitchintheworldhealthorganizationregionalofficeforafrica